Immunotherapy Continues to Show Promise in Treating Gastric Cancers Jul 15 2016 In the phase 1b JAVELIN trial, pretreated patients with gastric/gastroesophageal junction cancers (GC/GEJ) responded well to avelumab, a PD-L1 antibody.
